



APASL Oncology 2026 Tokyo

“Treatment Dynamics of Liver Tumors”

Scientific Program

APASL Oncology 2026 Tokyo Scientific Program

DAY 1, April 2 (Thursday) 2026

Room 1 “Ito Hall” B2F

9:00-9:10 **Opening Ceremony**

9:10-10:40 **Session 1**

“Current Management of Intrahepatic & Hilar CCA (I/H-CCA): Combined Treatment Strategies of Biliary Drainage and Anti-Cancer Therapy”

Moderators: Dr. Jae Hee Cho (Korea), Dr. Hiroyuki Isayama (Japan), Dr. Hirofumi Kogure (Japan)

S1-1 Biliary Drainage and Anti-tumor Therapy for I/H-CCA: Real-World Sequencing in Asia

Dr. Jae Hee Cho (Korea)

S1-2 Endoscopic Management of Biliary Obstruction in I/H-CCA

Dr. Hirofumi Kogure (Japan)

S1-3 IO-Based Chemotherapy and Matched Therapy in I/H-CCA: What’s New and When to Start?

Dr. Takashi Sasaki (Japan)

S1-4 Consideration of Treatment Dynamics of I/H CCA from Tokyo Criteria

Dr. Hiroyuki Isayama (Japan)

S1-5 Molecular Basis of Intrahepatic Cholangiocarcinogenesis and Its Therapeutic Implications

Dr. Hiroaki Fujiwara (Japan)

S1-6 Landscape of the Biliary Cancer-Field Elucidated by Minute Dissection-Based Molecular Mapping: Opening A New Path to Early Diagnosis

Dr. Yusuke Kouchi (Japan)

Discussion: Integrating Drainage, Pathology, and Systemic Therapy - What Is the Optimal Sequence?

10:40-11:00 **Coffee Break**

11:00-11:45 **Session 2**

“Beyond irAEs: When Hepatic Toxicity Signals Therapeutic Success?”

Moderators: Dr. Sadahisa Ogasawara (Japan), Dr. Tatsuo Kanda (Japan), Dr. Tomoharu Yamada (Japan)

S2-1 Beyond the Storm: Life After irAEs - The Hepatic Frontier

Dr. Sadahisa Ogasawara (Japan)

S2-2 Hepatic irAEs and Survival Benefit: What We Learned from 924 Patients

Dr. Tatsuo Kanda (Japan)

S2-3 Innovative Bridging Therapies for HCC: From Transarterial Chemoembolization to Immune Checkpoint Inhibitors

Dr. Tomoharu Yamada (Japan)

Discussion: irAE=Favorable Prognostic Marker or Selection Bias?

12:00-13:00 Luncheon Seminar 1 (AbbVie GK)

13:10-13:30 Keynote Lecture 1

“APASL and APASL ONCOLOGY”

Moderator: Dr. Shuntaro Obi (Japan)

Speaker: Dr. Masao Omata (Japan)

13:30-14:35 Session 3

“Biliary Drainage Before Chemotherapy: ERCP vs EUS-BD/A - The Gateway to Successful Treatment for I/H CCA”

Moderators: Dr. Yousuke Nakai (Japan), Dr. Naoki Sasahira (Japan), Dr. Rungsun Rerknimitr (Thailand)

S3-1 Video Lecture 1: Step-by-step ERCP for Malignant Biliary Obstruction before Chemotherapy

Dr. Rungsun Rerknimitr (Thailand)

S3-2 Video Lecture 2: EUS-guided Biliary Drainage/Anastomosis: Technical Pearls and Pitfalls

Dr. Sabro Matsubara (Japan)

S3-3 Does Quality of Biliary Drainage Affect Safety and Efficacy of Chemotherapy?

Dr. Yousuke Nakai (Japan)

S3-4 ERCP vs. EUS-BD/A ~Which should be the First-line Drainage? (Pro-ERCP)

Dr. Suguru Mizuno (Japan)

S3-5 Which should be the First-line Drainage? Pro-EUS

Dr. Kazuo Hara (Japan)

Discussion

14:35-14:50 **Coffee Break**

14:50-15:55 **Session 4**

“MASLD-Related HCC: From Risk Identification to Pharmacologic Prevention -Integrating Pathophysiology, Screening, and Intervention for the Next Era of HCC Prevention-”

Moderators: Dr. Yujin Hoshida (USA), Dr. Takumi Kawaguchi (Japan), Dr. Diana A. Payawal (Philippines)

S4-1 Epidemiologic Trends and Risk Factors for MASLD-related HCC in Asia

Dr. Diana A. Payawal (Philippines)

S4-2 Synergistic AI Approaches for Precision HCC Risk Stratification in MASLD: From Digital Pathology to Clinical Trajectory Prediction

Dr. Takuma Nakatsuka (Japan)

S4-3 Fibrosis, Stiffness Dynamics, and Cancer Risk: Lessons from Longitudinal Cohorts

Dr. Taeang Arai (Japan)

S4-4 Molecular Mechanisms of MASLD-related Hepatocarcinogenesis and Therapeutic Interception

Dr. Hayato Nakagawa (Japan)

S4-5 Pharmacologic Prevention of MASLD-related HCC: From SGLT2 Inhibitors to Next-Generation Metabolic Modulators

Dr. Takumi Kawaguchi (Japan)

Panel Discussion: “Integrating Translational Insights into Clinical Prevention”

15:55-16:15 **Special Session**

“From Idea to Impact: How Young Hepatologists Build Clinical Research Careers - Launching the APASL-Oncology School: Educating the Next Leaders in Liver Cancer Research –”

Moderator: Dr. Shuntaro Obi (Japan)

Speaker: Dr. Ryosuke Tateishi (Japan)

16:15-16:55 **Keynote Lecture 2**

“Medication for Prevention and Treatment”

Moderator: Dr. Masao Omata (Japan)

KL2-1 FGF21 Analogs in MASLD/MASH: From Metabolic Remodeling to Fibrosis Reversal and HCC Risk Modification

Dr. Motoyuki Otsuka (Japan)

KL2-2 Anti-cancer Medication on Horizon: Genomic Profiling and Immunotherapy Integration

Dr. Shigehisa Kitano (Japan)

17:00-18:00 **Evening Seminar** (Gilead Sciences K.K.)

“Twilight of HCV-Related HCC: A Decade of Interferon-Free Revolution in Japan”

ES-1 National Trends in HCV Eradication and HCC Mortality in Japan

ES-2 Long-term Liver Stiffness and Cancer Risk after SVR: Real-World Insights

Panel Discussion: Can Japan’s Model Inform Global HCV Elimination?

18:00-19:00 **Poster Sessions at “Gallery 1&2” B1F, “Event Space” B2F**

19:00-20:30 **Welcome Reception at “Event Stage” B2F**

APASL Oncology 2026 Tokyo Scientific Program

DAY 1, April 2 (Thursday) 2026

Room 2 “Seminar Room” 3F

9:10-10:00 **Oral Free Paper Session 1**

10:00-10:45 **Oral Free Paper Session 2**

11:00-11:50 **Oral Free Paper Session 3**

12:00-13:00 **Luncheon Seminar 2 (Eisai Co., Ltd.)**

13:30-14:02 **Late Breaking Session 1**

14:02-14:35 **Late Breaking Session 2**

14:50-15:30 **Oral Free Paper Session 4**

15:30-16:00 **Oral Free Paper Session 5**

APASL Oncology 2026 Tokyo Scientific Program

DAY 1, April 2 (Thursday) 2026

Poster Sessions “Gallery 1&2” B1F, “Event Space” B2F

18:00-19:00 **Poster Free Paper Sessions**

APASL Oncology 2026 Tokyo Scientific Program

DAY 2, April 3 (Friday) 2026

Room 1 “Ito Hall” B2F

9:00-10:30 **Session 5**

“Systemic Therapy for HCC: Asia-Pacific Treatment Dynamics”

Moderators: Dr. Masatoshi Kudo (Japan), Dr. Ryosuke Tateishi (Japan), Dr. Yi-Hsiang Huang (Taiwan)

S5-1 How Do We Decide the Best First-line Therapy?

Dr. George Lau (Hong Kong SAR, China)

S5-2 Mainland China Perspective: Access, Sequence, and New Combination Strategies

Dr. Lai Wei (China)

S5-3 Taiwan Experience: Balancing TKI, ICI, and Real-world Constraints

Dr. Yi-Hsiang Huang (Taiwan)

S5-4 Systemic Therapy for Advanced Hepatocellular Carcinoma in the Era of Combination Immunotherapy: Real-world Treatment Sequences and Outcomes from the HERITAGE Study

Dr. Yoshinari Asaoka (Japan)

S5-5 How Do We Sequence Systemic Therapy in Daily Practice?

Dr. Sadahisa Ogasawara (Japan)

S5-6 Systemic Therapy Biomarkers: Translating Molecular Signatures into Clinical Decisions

Dr. Takahiro Kodama (Japan)

S5-7 The Evolving Landscape of Systemic Therapy

Dr. Ryosuke Tateishi (Japan)

Discussion

10:30-10:45 **Coffee Break**

10:45-11:50 **Session 6**

“Surgical Resectability and Liver Transplantation for HCC: Redefining the Boundaries Across Asia”

Moderators: Dr. Etsuro Hatano (Japan), Dr. Kiyoshi Hasegawa (Japan), Dr. Itsuko Chih-Yi Chen (Taiwan)

- S6-1 The Experience of Liver Transplantation for HCC in Qingdao**
Dr. Cai Jinzhen (China)
- S6-2 Optimizing Outcomes of Living Donor Liver Transplantation for Hepatocellular Carcinoma**
Dr. Itsuko Chih-Yi Chen (Taiwan)
- S6-3 How We Define Resectability of HCC in Practice**
Dr. Junichi Shindo (Japan)
- S6-4 The Concept of Borderline Resectable HCC: Japanese Perspective**
Dr. Etsuro Hatano (Japan)

Discussion

12:00-13:00 Luncheon Seminar 3 (Chugai Pharmaceutical Co., Ltd.)

13:10-13:30 Keynote Lecture 3

“Overwhelming Number of HCC Cases with Portal Hypertension: Address a Big Challenge”

Moderators: Dr. Masao Omata (Japan), Dr. Shuntaro Obi (Japan)

Speaker: Dr. Shiv K Sarin (India)

13:30-14:45 Session 7

“A-HOC Rising: Advancing Hepatocellular Carcinoma Care through Regional Collaboration”

Moderators: Dr. Ryosuke Tateishi (Japan), Dr. Motoyuki Otsuka (Japan), Dr. Amarsanaa Jazag (Mongolia)

- S7-1 What is A-HOC? Consortium Vision, Structure, and Activities: APASL Oncology = Platform for A-HOC Expansion**
Dr. Shuntaro Obi (Japan)
- S7-2 Building a Unified HCC Dataset: Turkey’s Contribution to A-HOC’s Regional Evidence Platform**
Dr. A. Kadir Dokmeci (Turkey)
- S7-3 A-HOC Data: Creating New Research Opportunities for Young Investigators**
Dr. Yasuto Takeuchi (Japan)
- S7-4 Country Spotlight: HCC Practice and Data Needs in Mongolia**
Dr. Amarsanaa Jazag (Mongolia)

S7-5 Uniting Islands, Uniting Data: Indonesia's Role in the A-HOC Network

Dr. Rino Gani (Indonesia)

S7-6 Empowering Regional Collaboration and Education: Thailand's Role in A-HOC

Dr. Teerha Piratvisuth (Thailand)

Discussion

Comment by Dr. Masao Omata (As founder)

14:45-15:00 **Coffee Break**

15:00-16:05 **Session 8**

"Image-Guided Interventions for HCC: Regional Practice, Education, and Future Directions"

Moderators: Dr. Shuichiro Shiina (Japan), Dr. Toshihiro Tanaka (Japan), Dr. Kai-Wen Huang (Taiwan)

S8-1 Dissemination and Education of RFA and MWA in the Asia-Pacific Region

Dr. Shuichiro Shiina (Japan)

S8-2 Local Ablation for HCC: Training and Skill Advancement in Taiwan

Dr. Kai-Wen Huang (Taiwan)

S8-3 ReMAP-Based Transarterial Embolization: Toward Personalized IVR

Dr. Toshihiro Tanaka (Japan)

S8-4 The Evolution of Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: Multidisciplinary Strategies in the Era of Chemo-diversity

Dr. Hideki Iwamoto (Japan)

S8-5 Heavy Ion Radiotherapy for HCC: A New Frontier in Interventional Oncology

Dr. Hirokazu Makishima (Japan)

Discussion

16:05-16:45 **Plenary Session**

16:45-17:00 **Awarding & Closing Ceremony**

APASL Oncology 2026 Tokyo Scientific Program

DAY 2, April 3 (Friday) 2026

Room 2 “Seminar Room” 3F

9:00-10:30 **Video Session**

10:45-11:17 **Oral Free Paper Session 7**

11:17-11:50 **Oral Free Paper Session 8**

13:30-13:55 **Oral Free Paper Session 9**

13:55-14:15 **Oral Free Paper Session 10**

14:15-14:45 **Oral Free Paper Session 11**

15:00-15:32 **Young Investigator Award Session 1**

15:32-16:05 **Young Investigator Award Session 2**

APASL Oncology 2026 Tokyo Scientific Program

DAY 2, April 3 (Friday) 2026

Poster Sessions “Gallery 1&2” B1F, “Event Space” B2F

15:00-16:00 **Poster Free Paper Sessions**
